Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369
Summary Background Drugs that inhibit the renin-angiotensin-aldosterone system benefi t patients at risk for or with existing cardiovascular disease. However, evidence for this eff ect in Asian populations is scarce. We aimed to investigate whether addition of an angiotensin receptor blocker, valsartan, to conventional cardiovascular treatment was eff ective in Japanese patients with cardiovascular disease
